Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Voyager TherapeuticsFRA:VT6 -4.30%42 Days Sales Outstanding is 63.73 as of Jun. 2026, which is 46% below its 10-year median of 117.02. GuruFocus rates FRA:VT6 with a GF Score™ of 42/100 and a GF Value™ of €1.14 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 841 Biotechnology companies, Voyager Therapeutics ranks better than 88.47% on this metric.
Voyager Therapeutics (FRA:VT6) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Voyager Therapeutics Days Sales Outstanding Related Terms
Voyager Therapeutics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Voyager Therapeutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VT6 vs CHRS, KROS, DTIL: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Voyager Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voyager Therapeutics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Voyager Therapeutics's Days Sales Outstanding falls into.
Voyager Therapeutics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Voyager Therapeutics (FRA:VT6) has a Days Sales Outstanding of 63.73 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Voyager Therapeutics and its competitors. This is 46% below median its historical median of 117.02. Over the past decade, Voyager Therapeutics' Days Sales Outstanding has ranged from 14.76 to 186.27. According to the industry distribution chart, Voyager Therapeutics ranks #97 out of 841 companies in the Biotechnology industry, placing it in the top 11.5%.
Is Voyager Therapeutics' Days Sales Outstanding too high?
Voyager Therapeutics' current Days Sales Outstanding of 63.73 is 46% below median its 10-year median of 117.02. Over the past 10 years, this metric has ranged from a low of 14.76 to a high of 186.27. The Biotechnology industry median Days Sales Outstanding is 68.94. Voyager Therapeutics' value of 63.73 is 7.6% below this industry median. Based on the distribution chart, Voyager Therapeutics ranks #97 out of 841 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Voyager Therapeutics has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' Days Sales Outstanding compare to CHRS and KROS?
According to the Biotechnology industry distribution chart, Voyager Therapeutics ranks #97 out of 841 companies for Days Sales Outstanding. This places Voyager Therapeutics in the top 12% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 68.94. Voyager Therapeutics' value of 63.73 is 7.6% below this benchmark. Historically, Voyager Therapeutics' own Days Sales Outstanding has ranged from 14.76 to 186.27 over the past decade. While the company's 10-year median is 117.02 vs. the industry median of 68.94, Voyager Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Voyager Therapeutics's current Days Sales Outstanding of 63.73 is 7.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Voyager Therapeutics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Voyager Therapeutics's current Days Sales Outstanding is 63.73, which is 46% below median its own 10-year median of 117.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (FRA:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.14, compared to a current price of €2.67 — trading 134% above its estimated fair value. The current Days Sales Outstanding is 63.73, which is 46% below median its 10-year median of 117.02 and 7.6% below the Biotechnology industry median of 68.94. Voyager Therapeutics' overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Voyager Therapeutics (FRA:VT6), the current Days Sales Outstanding is 63.73 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?
Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued.
The current stock price of €2.67 is trading 134% above its estimated GF Value™ of €1.14.
GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:VT6:
Days Sales Outstanding: 63.73 (46% below median its 10-year median of 117.02)
GF Value™: €1.14 vs. price of €2.67 (134% above fair value)
Industry Position: 7.6% below the Biotechnology median (#97 of 841)
No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
42GF Score
Get the complete analysis for FRA:VT6
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VT6 has been successfully added to your 
